Positions

Overview

  • Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusInternational Journal of Parallel Programming.  71:1125-1134. 2019
    2019 Ifnγ induces epigenetic programming of human t-bethi b cells and promotes tlr7/8 and il-21 induced differentiationOverview.  8. 2019
    2019 Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trialPLoS Medicine.  16. 2019
    2019 Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception CohortJournal of Rheumatology.  46:492-500. 2019
    2019 Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosusJournal of Autoimmunity2019
    2018 Cutting edge: Intracellular IFN-β and distinct type i IFN expression patterns in circulating systemic lupus erythematosus B cellsJournal of Immunology.  201:2203-2208. 2018
    2018 Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort StudyBiomedicines.  70:1478-1487. 2018
    2017 A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosusLupus.  26:1483-1490. 2017
    2017 Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsInternational Journal of Parallel Programming.  69:362-375. 2017
    2016 Extensive Pyoderma Gangrenosum Associated with Granulomatosis with Polyangiitis with Both Responsive to RituximabJCR: Journal of Clinical Rheumatology.  22:392-394. 2016
    2016 A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosisJournal of Immunology.  196:2492-2503. 2016
    2016 Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial∗Clinical pharmacy.  44:275-281. 2016
    2016 Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genesAccounting Educators' Journal.  34:953. 2016
    2015 Minorities with lupus nephritis and medications: A study of facilitators to medication decision-makingMicrosurgery.  17. 2015
    2015 Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosusInternational Journal of Parallel Programming.  67:1848-1857. 2015
    2015 Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group techniqueJournal of Rheumatology.  42:1616-1623. 2015
    2015 Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?Journal of Rheumatology.  42:1078-1080. 2015
    2015 Vasculitis related to viral and other microbial agentsEMBO Journal.  29:226-243. 2015
    2014 Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurementsLupus Science & Medicine.  1. 2014
    2014 Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJournal of Rheumatology.  41:300-309. 2014
    2014 Macrophage Activation Syndrome Secondary to Human Monocytic EhrlichiosisIndian Journal of Hematology and Blood Transfusion.  30:145-147. 2014
    2013 Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell PopulationsPLoS Genetics.  9. 2013
    2012 Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusCancer Genetics and Cytogenetics.  64:4040-4047. 2012
    2012 Device for carrying blood samples at 37°C for cryoglobulin testCAIS.  19:1555-1556. 2012
    2012 Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trialJournal of Rheumatology.  39:1632-1640. 2012
    2012 Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusCancer Genetics and Cytogenetics.  64:2328-2337. 2012
    2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisBiomedicines.  64:635-639. 2012
    2012 Systemic lupus erythematosus: Genomics, mechanisms, and therapiesPhilosophy of Science.  2012. 2012
    2011 A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusCancer Genetics and Cytogenetics.  63:3918-3930. 2011
    2011 B lymphocytes are resistant to death receptor 5-induced apoptosisCancer Prevention Research.  139:21-31. 2011
    2010 Report of the American College of Rheumatology Pain Management Task ForceBiomedicines.  62:590-599. 2010
    2010 Rheumatic manifestations of systemic disease: SarcoidosisAustralian Family Physician.  22:85-90. 2010
    2009 A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusBiomedicines.  61:1168-1178. 2009
    2009 Novel evidence-based systemic lupus erythematosus responder indexBiomedicines.  61:1143-1151. 2009
    2009 Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritisScandinavian Journal of Immunology.  70:309-316. 2009
    2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityJournal of Clinical Investigation.  119:1668-1677. 2009
    2008 Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosusMicrosurgery.  10. 2008
    2008 Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusCancer Genetics and Cytogenetics.  58:2453-2459. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisBiomedicines.  59:762-784. 2008
    2006 Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? CommentaryNature Clinical Practice Rheumatology.  2:240-241. 2006
    2006 Improving ambulatory prescribing safety with a handheld decision support system: A randomized controlled trialJournal of the American Medical Informatics Association.  13:171-179. 2006
    2006 Ultrasound appearance of knuckle pads.Skeletal Radiology.  35:823-827. 2006
    2005 Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosusCancer Genetics and Cytogenetics.  52:3943-3954. 2005
    2003 FcγRIIIb Allele-Sensitive Release of α-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of ChemotaxinsJournal of Immunology.  171:6090-6096. 2003
    2002 Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imagingJournal of Rheumatology.  29:2463-2465. 2002
    2002 Immune function in patients with rheumatoid arthritis treated with etanerceptCancer Prevention Research.  103:13-21. 2002
    2001 Treatment of lupus with corticosteroidsLupus.  10:140-147. 2001
    2000 Renal failure: A risk factor for methotrexate toxicityCancer Genetics and Cytogenetics.  43:1185-1186. 2000
    1999 Update on sarcoidosisAustralian Family Physician.  11:83-87. 1999
    1998 Ligation of CR1 attenuates Fc receptor-mediated myeloperoxidase release and HOCl production by neutrophilsJournal of Leukocyte Biology.  63:477-485. 1998
    1996 Acidic fibroblast growth factor (FGF-1) enhances huvec expression of ICAM-1 induced by IL-1βFederation proceedings.  10. 1996
    1996 Characterization of PepB, a group B streptococcal oligopeptidaseInfection and Immunity.  64:3401-3406. 1996
    1995 Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidaseInformation, Communication and Society.  50:811-814. 1995
    1995 Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenaseAntioxidants.  76:241-247. 1995
    1995 Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritisCancer Genetics and Cytogenetics.  38:1328-1332. 1995
    1995 Rheumatoid synovial fibroblast adhesion to human articular cartilageCancer Genetics and Cytogenetics.  38:1694-1700. 1995
    1994 Determinants of neutrophil HOCl generation: Ligand-dependent responses and the role of surface adhesionJournal of Leukocyte Biology.  56:654-660. 1994
    1994 HOCl production by human neutrophils activated by surface-associated IgG: Requirement for influx of extracellular calciumJournal of Leukocyte Biology.  55:793-797. 1994
    1993 Degradation of human articular cartilage by neutrophils in synovial fluidCancer Genetics and Cytogenetics.  36:51-58. 1993
    1993 Fixation of C3 to IgG attenuates neutrophil HOCl generation and collagenase activationJournal of Immunology.  151:949-958. 1993
    1992 Additive enhancement of neutrophil collagenase activity by HOCl and cathepsin GJournal of Healthcare Leadership.  184:560-567. 1992
    1992 Ligand dependent release of activated neutrophil collagenase--a role for surface bound IgG in the degradation of articular collagens.Matrix (Stuttgart, Germany). Supplement.  1:207-208. 1992
    1991 Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenaseCancer Genetics and Cytogenetics.  34:211-216. 1991
    1990 Letter to the editor (I)Cancer Genetics and Cytogenetics.  3:104-105. 1990
    1990 Letter to the editor (I)Cancer Genetics and Cytogenetics.  3:104-105. 1990
    1990 LettersCancer Genetics and Cytogenetics.  3:104-105. 1990
    1990 Ligand‐dependent release of active neutrophil collagenaseCancer Genetics and Cytogenetics.  33:228-234. 1990
    1990 Lysis of fibrillar collagen by neutrophils in synovial fluid. A Role for Surface‐Bound ImmunoglobulinsCancer Genetics and Cytogenetics.  33:1333-1339. 1990
    1989 The replyElectronic Journal of Biotechnology.  86:634. 1989
    1989 Valvular Heart Disease in Systemic Lupus ErythematosusNew England Journal of Medicine.  320:739-741. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Cancer Genetics and Cytogenetics.  2:70-74. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Cancer Genetics and Cytogenetics.  2:70-74. 1989
    1988 Cell Surface Receptors for Kidney Basement MembranesOregon Social Studies Journal.  12:78-83. 1988
    1988 Clinically significant valvular heart disease in systemic lupus erythematosusElectronic Journal of Biotechnology.  85:645-650. 1988
    1983 Leukemoid Blood Reaction to TetracyclineSouthern Medical Journal.  76:1195-1196. 1983

    Chapter

    Year Title Altmetric
    2018 Management of autoimmune and inflammatory disorders in the setting of infection or immunodeficiency.  427-443. 2018

    Research Overview

  • Lupus
    Immunodeficiency associated autoimmunity
    Macrophage activation syndrome
  • Principal Investigator On

  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2019 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2021
  • Private Grant  awarded by MedImmune 2013 - 2021
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY 2019 - 2021
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2017 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2018 - 2021
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2019 - 2021
  • Private Grant  awarded by AKER BIOMARINE ANTARCTIC 2019 - 2021
  • Private Grant  awarded by Human Genome Sciences 2014 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2020
  • Private Grant  awarded by Gilead Sciences 2018 - 2020
  • Lupus Clinical Investigators Network (LuCIN)  awarded by LUPUS THERAPEUTICS LLC 2018 - 2019
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2017 - 2019
  • Private Grant  awarded by UCB BIOSCIENCES 2016 - 2019
  • Private Grant  awarded by BENAROYA RESEARCH INSTITUTE 2015 - 2019
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by MedImmune 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2018
  • Private Grant  awarded by EMD SERONO 2014 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by ABLYNX NV 2016 - 2018
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2018
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2018
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2016 - 2017
  • Private Grant  awarded by CELGENE CORPORATION 2014 - 2017
  • Private Grant  awarded by EMD SERONO 2014 - 2016
  • Private Grant  awarded by BIOGEN IDEC, INC. 2015 - 2016
  • Private Grant  awarded by Human Genome Sciences 2008 - 2016
  • Private Grant  awarded by Human Genome Sciences 2003 - 2016
  • Private Grant  awarded by IPSOS-INSIGHT, LLC 2014 - 2016
  • Private Grant  awarded by Human Genome Sciences 2012 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2015
  • Private Grant  awarded by UCB, INC. 2011 - 2015
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2015
  • Private Grant  awarded by MedImmune 2012 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2014 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2014 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2014
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2012 - 2014
  • A Randomized Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs. Cyclophosphamide Alone in the Treatment of Lupus Nephritis - The Start Up Phase of Clinical Trial ITN #INT034AI  awarded by University of California, San Francisco 2008 - 2014
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2012 - 2013
  • Private Grant  awarded by Genentech 2009 - 2013
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2010 - 2013
  • Private Grant  awarded by CEPHALON, INC. 2011 - 2013
  • Private Grant  awarded by EMD SERONO 2008 - 2013
  • Private Grant  awarded by Human Genome Sciences 2008 - 2013
  • Private Grant  awarded by Centocor 2011 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2013
  • Private Grant  awarded by MedImmune 2010 - 2012
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2012
  • Private Grant  awarded by UCB PHARMA, INC. 2007 - 2012
  • Private Grant  awarded by CEPHALON, INC. 2010 - 2012
  • Effect of Vitamin D3 on the IFNa Signature in Patients with Systemic Lupus Erythmatosus - ACE  awarded by Duke University 2009 - 2012
  • Private Grant  awarded by Human Genome Sciences 2007 - 2011
  • Mapping Autoimmune Phenotypes in Multiplex Families  awarded by FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 2010 - 2011
  • Private Grant  awarded by Genentech 2007 - 2011
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2007 - 2011
  • Private Grant  awarded by CYPRESS BIOSCIENCE 2010 - 2011
  • Private Grant  awarded by Human Genome Sciences 2004 - 2010
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2010
  • Teaching Activities

  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Spring Term 2019) 2019
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Spring Term 2019) 2019
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Spring Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Spring Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Spring Term 2019) 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018 - 2019
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2016) 2016
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2016) 2016
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • 28-490 - RHEUMATOLOGY (Spring Term 2016) 2016
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2016) 2016
  • 28-490 - RHEUMATOLOGY (Spring Term 2016) 2016
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2016) 2016
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2015) 2015
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • 28-490 - RHEUMATOLOGY (Fall Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Fall Term 2014) 2014
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Fall Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Spring Term 2012) 2012
  • 95-577 - RHEUMATOLOGY SELECTIVE (Spring Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Spring Term 2012) 2012
  • 95-577 - RHEUMATOLOGY SELECTIVE (Fall Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Fall Term 2011) 2011
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Fall Term 2011) 2011
  • 95-577 - RHEUMATOLOGY CLINICAL SELECTIVE (Spring Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Spring Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Spring Term 2011) 2011
  • 95-577 - RHEUMATOLOGY CLINICAL SELECTIVE (Spring Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Spring Term 2011) 2011
  • 28-490 - RHEUMATOLOGY (Fall Term 2010) 2010
  • 28-490 - RHEUMATOLOGY (Fall Term 2010) 2010
  • 95-577 - RHEUMATOLOGY CLINICAL SELECTIVE (Fall Term 2010) 2010
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2010) 2010
  • 95-577 - RHEUMATOLOGY CLINICAL SELECTIVE (Fall Term 2010) 2010
  • 28-490 - RHEUMATOLOGY (Spring Term 2010) 2010
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • PCL1180 - MUSCULOSKELETAL/SKIN (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2008) 2008
  • PCL1180 - MUSCULOSKELETAL / SKIN (Spring Term 2008) 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • Education And Training

  • University of North Carolina Hospital, Internship
  • Doctor of Medicine, Vanderbilt University 1980
  • Bachelor's Degree in General Studies, Duke University 1976
  • University of North Carolina Hospital, Residency 1983
  • UAB Hospital, Postdoctoral Fellowship 1989
  • Full Name

  • W. Winn Chatham